# A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment

Source: https://onco.cc/trials/nct06746116/  
OnCo record `nct06746116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab in endometrial cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain is a phase 3 interventional study registered as NCT06746116 by AstraZeneca, with 45 participants enrolled, started 2024-12-30 and due to reach its primary completion in 2028-11-30. Interventions recorded: Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase. Conditions listed: Advanced or Recurrent Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06746116
- Phase: 3
- Setting: A Phase IIIB Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Patients With Newly Diagnosed pMMR Advanced or Recurrent Endometrial Cancer in Spain
- Sponsor: AstraZeneca
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT06746116: https://clinicaltrials.gov/study/NCT06746116

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06746116.json